Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation

Company Grants Teva a License to Market Generic VIVITROL Beginning in January 2027 DUBLIN, Aug. 30, 2023 -- (Healthcare Sales & Marketing Network) -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with ... Biopharmaceuticals, Litigation, Licensing Alkermes, Teva Pharmaceutical, VIVITROL, naltrexone
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news